Coburn BW, et al. - Researchers ascertained whether or not allopurinol dose escalation was associated with cause-specific mortality in patients with gout. Till date, this is the largest study to gauge the impacts of allopurinol use on mortality and is the first to use a rigorous active-comparator design. In all-cause mortality, a correlation between the dose escalation and a small (<10%) increase was seen. This association demonstrated the unlikeliness of a strategy of allopurinol dose escalation, which in current real-life practice is characterized by limited dose increases, to improve the survival of patients with gout.